Intermediate vancomycin susceptibility in a community-associated MRSA clone.
about
Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicDaptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsMechanisms of vancomycin resistance in Staphylococcus aureusAntibacterial Evaluation of Synthetic Thiazole Compounds In Vitro and In Vivo in a Methicillin-Resistant Staphylococcus aureus (MRSA) Skin Infection Mouse ModelIdentification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycinEvolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureus.Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.Antibiotic options for treating community-acquired MRSA.Diversity of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from inpatients of 30 hospitals in Orange County, CaliforniaReduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of Infective Endocarditis in ArgentinaAn evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children.Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.Recurrent furunculosis caused by a community-acquired Staphylococcus aureus strain belonging to the USA300 clone.First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agentMultiplex PCR for rapid detection of Staphylococcus aureus isolates suspected to represent community-acquired strains.Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia modelsGenetic Characterization of Methicillin Resistant and Sensitive, Vancomycin Intermediate Staphylococcus aureus Strains Isolated from Different Iranian HospitalsDaptomycin in bone and joint infections: a review of the literature.Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America.Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.Community-Associated Methicillin-Resistant Staphylococcus aureus in the Pediatric Population.Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Genetic alterations responsible for reduced susceptibility to vancomycin in community-associated MRSA strains of ST72.Bacteriological profiling of diphenylureas as a novel class of antibiotics against methicillin-resistant Staphylococcus aureus.Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.The rise of antimicrobial resistance: a clear and present danger.
P2860
Q24614464-986A4D0B-09BF-4E8F-9C49-1C192E28FF28Q24620644-C73549A5-5B00-4611-8427-E42DA3E975E3Q24646677-D43E3D7B-5DEC-4D35-9378-C08F042DC3A0Q26829312-272A2FD9-4ECD-41B6-8784-73387538702EQ28550691-D9E2784A-1431-48D0-A92E-C6EA3CFE3AE7Q30394525-72AA52B4-7F4C-41F0-8A59-B361FBA929AAQ34116509-AA0BB2C1-0C2F-452F-997F-29EC25C912FEQ34343212-B23A9642-C77B-45B9-9EC8-9E88282AD12EQ34477769-24CF88FF-8D4D-4E55-9A7B-2B621979405FQ34593646-30813AE8-8C0C-4619-8896-D770F451E802Q34700948-6B3564C5-2844-4503-88EA-391015B11437Q34998629-75734FC1-4DAC-4895-AFD5-D858FD110104Q35035275-BA7D66DE-3D72-4A52-B77E-8BA035A4AE89Q35618211-A57E732D-71BB-43D3-A598-416CDDB0FE97Q35728976-BAB7C02D-54BB-484D-90EA-21B12C69B024Q35900384-8831556A-64C0-4ACF-82AE-62B784B8C984Q36118613-753FE723-B14D-45C8-97B6-169DCA83A846Q36265781-F618C114-8380-48C7-B085-3D1D636C2313Q36452505-1B1451FD-9062-4A50-9269-C5F117B279A4Q36569841-27C871B5-4258-45F4-9EF2-CF7AA636BE5EQ36876054-A9461177-C088-4E26-9711-BA6E68A1D341Q37319460-C233833A-463C-458A-8136-276FEB24261AQ37455462-70C765E4-F01A-44E6-9D73-81EAC4746FFEQ37819539-6E0B827B-E874-40FE-AA3F-9F923B41CEC1Q38051319-3A0BC53F-E0DF-40A7-B74C-028C7D2E650BQ38075466-557D8D9C-7DC6-4202-9CFE-953CE109966BQ38462842-FB7FCF94-6F3D-471B-AC71-48571082FAB6Q38736105-F96DF273-0A40-4C00-A2CD-1B21346DA458Q40098505-7E8A6049-A88B-423A-B4C8-56F7E99E38AEQ40988669-8D138B27-E673-40E1-81CF-BFEC0DA54616Q42003878-44969BD2-16A2-4D73-8622-FF864858E0C9Q51165933-2FFA750E-F155-4DEA-B589-54D10B555B97
P2860
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@en
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@nl
type
label
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@en
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@nl
prefLabel
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@en
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@nl
P2093
P2860
P356
P1476
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
@en
P2093
Barbara L Haller
Christopher J Graber
Françoise Perdreau-Remington
Heather A Carleton
Henry F Chambers
Margaret K Wong
P2860
P304
P356
10.3201/EID1303.060960
P577
2007-03-01T00:00:00Z